News
DMRA
20.91
-0.48%
-0.10
Damora Therapeutics (DMRA) Receives a Buy from TD Cowen
TipRanks · 1d ago
DAMORA THERAPEUTICS INC <DMRA.O>: TD COWEN INITIATES COVERAGE WITH BUY RATING
Reuters · 1d ago
Weekly Report: what happened at DMRA last week (0601-0605)?
Weekly Report · 1d ago
Damora Therapeutics grants options for 372,000 shares to new hires at $24.88 each
PUBT · 06/01 12:02
DAMORA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 06/01 12:00
Weekly Report: what happened at DMRA last week (0525-0529)?
Weekly Report · 06/01 09:29
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
NASDAQ · 05/30 18:12
Wedbush bullish on Damora Therapeutics, initiates with an Outperform
TipRanks · 05/28 13:39
Damora Therapeutics Price Target Announced at $35.00/Share by Wedbush
Dow Jones · 05/28 13:09
Wedbush Initiates Coverage On Damora Therapeutics with Outperform Rating, Announces Price Target of $35
Benzinga · 05/28 12:58
Damora Therapeutics initiated with an Outperform at Wedbush
TipRanks · 05/28 12:08
DAMORA THERAPEUTICS INC <DMRA.O>: WEDBUSH INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $35
Reuters · 05/28 10:52
Damora Therapeutics: Well-Funded Moonshot For CALR Mutations
Seeking Alpha · 05/27 11:22
Weekly Report: what happened at DMRA last week (0518-0522)?
Weekly Report · 05/25 09:31
Weekly Report: what happened at DMRA last week (0511-0515)?
Weekly Report · 05/18 09:30
Damora Therapeutics (DMRA) Receives a Rating Update from a Top Analyst
TipRanks · 05/17 16:48
Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (DMRA), Cormedix (CRMD) and AnaptysBio (ANAB)
TipRanks · 05/15 15:20
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology
Reuters · 05/14 07:24
DAMORA THERAPEUTICS INC <DMRA.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $51 FROM $55
Reuters · 05/14 03:24
Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (DMRA) and vTv Therapeutics (VTVT)
TipRanks · 05/14 01:00
More
Webull provides a variety of real-time DMRA stock news. You can receive the latest news about DAMORA THERAPEUT through multiple platforms. This information may help you make smarter investment decisions.
About DMRA
Damora Therapeutics Inc, formerly Galecto, Inc, is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company is engaged in the advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. It offers a multiple programs including asset, DMR-001, an investigational monoclonal antibody therapy targeting mutCALR. DMR-001 was designed to exclusively bind to mutCALR with exquisite selectivity, potency, and extended half-life, with potential to enable convenient, infrequent subcutaneous dosing.